Arora Parul, Sagar Rajesh, Mehta Manju, Pallavi Pooja, Sharma Subhadra, Mukhopadhyay Asok Kumar
Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi, India.
Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, India.
Indian J Psychiatry. 2019 Jan-Feb;61(1):70-76. doi: 10.4103/psychiatry.IndianJPsychiatry_391_16.
The biochemical basis of depression has been related to blood-brain barrier (BBB) allowing/restricting a number of components to enter the brain milieu from the peripheral plasma milieu. S100B has been associated with BBB damage and is used as a marker of its integrity. Several studies have reported that depressive patients have increased levels of S100B in serum and cerebrospinal fluid.
Forty-two confirmed cases of depression, 13-25 years of ages were recruited from the Department of Psychiatry, All India Institute of Medical Sciences during the period from January 2013 to June 2014 along with 42 healthy controls of comparable age and sex. Psychometric evaluation of the patients and controls was done to assess the severity of depression using Beck's Depression Inventory-II and Hamilton Depression Rating Scale. Medical assessment and laboratory investigations were done. Serum S100B levels were measured using Sandwich ELISA. The results obtained were statistically analyzed.
Levels of serum S100B were significantly elevated in patients with major depression as compared to controls. Significantly higher levels of S100B were seen only in females as compared to their healthy counterparts. Serum S100B was higher in depressed participants with the recurrent disorder than those with single episode. No correlation of levels of this marker was seen with clinical severity of the patients. It was found that with increased duration of illness for which the patient was being treated with antidepressants, the patients had higher levels of S100B.
Serum S100B can be used as a biomarker of depression.
抑郁症的生化基础与血脑屏障（BBB）有关，血脑屏障允许/限制多种成分从外周血浆环境进入脑内环境。S100B与血脑屏障损伤有关，并被用作其完整性的标志物。多项研究报告称，抑郁症患者血清和脑脊液中的S100B水平升高。
2013年1月至2014年6月期间，从全印度医学科学研究所精神病科招募了42例确诊的抑郁症患者，年龄在13至25岁之间，同时招募了42名年龄和性别相仿的健康对照者。使用贝克抑郁量表-II和汉密尔顿抑郁评定量表对患者和对照者进行心理测评，以评估抑郁的严重程度。进行了医学评估和实验室检查。采用夹心酶联免疫吸附测定法测量血清S100B水平。对获得的结果进行统计学分析。
与对照组相比，重度抑郁症患者的血清S100B水平显著升高。与健康女性相比，仅在女性中观察到S100B水平显著更高。复发性抑郁症患者的血清S100B水平高于单次发作患者。未发现该标志物水平与患者临床严重程度相关。研究发现，随着患者接受抗抑郁药治疗的病程延长，患者的S100B水平更高。
血清S100B可作为抑郁症的生物标志物。
